| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 39.89M | 39.77M | 25.87M | 2.67M | 6.01M | 12.44M |
| Gross Profit | 1.09M | 968.93K | 843.62K | 60.17K | 551.40K | 1.78M |
| EBITDA | -3.33M | -3.39M | -5.85M | -2.11M | -4.78M | -19.71M |
| Net Income | -3.42M | -3.48M | -6.28M | -3.03M | -6.18M | -20.12M |
Balance Sheet | ||||||
| Total Assets | 8.30M | 8.30M | 4.37M | 6.37M | 10.08M | 17.34M |
| Cash, Cash Equivalents and Short-Term Investments | 1.72M | 1.72M | 2.03M | 1.55M | 3.04M | 4.26M |
| Total Debt | 1.16M | 1.16M | 2.19M | 0.00 | 520.24K | 3.06M |
| Total Liabilities | 5.64M | 5.64M | 3.80M | 1.26M | 5.98M | 11.98M |
| Stockholders Equity | 2.55M | 2.55M | 524.74K | 5.11M | 4.18M | 5.39M |
Cash Flow | ||||||
| Free Cash Flow | -4.26M | -4.26M | -2.84M | -3.46M | -5.35M | -10.48M |
| Operating Cash Flow | -4.26M | -4.26M | -2.66M | -3.46M | -4.64M | -7.99M |
| Investing Cash Flow | -38.83K | -38.83K | -318.20K | -192.52K | 589.87K | -2.59M |
| Financing Cash Flow | 3.93M | 3.93M | 3.58M | 2.00M | 2.59M | 6.59M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | AU$49.12M | 3.88 | 24.28% | 21.25% | 2.76% | 1.93% | |
76 Outperform | AU$82.84M | 3.79 | 34.61% | 17.44% | 6.15% | -32.02% | |
61 Neutral | $18.38B | 12.79 | -2.54% | 3.03% | 1.52% | -15.83% | |
40 Underperform | ― | ― | ― | ― | ― | ― | |
37 Underperform | ― | ― | -226.65% | ― | 53.75% | 57.58% | |
37 Underperform | ― | ― | ― | ― | -100.00% | 33.55% |
AuMake Limited has announced the issuance of fully paid ordinary shares without disclosure under Part 6D.2 of the Corporations Act, as per the notice under section 708A(5)(e). The company confirms compliance with relevant provisions of the Corporations Act and states that there is no excluded information that would typically be expected in a disclosure document. This move signifies AuMake’s strategic approach to managing its share capital and maintaining transparency with its investors.
AuMake Limited, listed on the Australian Securities Exchange under the code AUK, has announced the quotation of 55 million ordinary fully paid securities as of December 5, 2025. This move is part of the company’s strategic financial activities, potentially impacting its market position and offering new opportunities for stakeholders.
AuMake Ltd. announced the resignation of Director Jiahua (Joshua) Zhou, effective November 28, 2025. Zhou’s departure involves the transfer of his interests in 117,560,672 ordinary shares held by Zhous Australia Holding Pty Ltd. This change in leadership may impact the company’s strategic direction and stakeholder interests.
AuMake Limited has announced the cessation of Zhao Zhang as a director, effective from November 28, 2025. Zhao Zhang, who held significant interests in the company through New Continent Australia Pty Ltd, had 100 million fully paid ordinary shares and 100 million unquoted options. This change in directorship may impact the company’s governance and strategic direction, potentially affecting stakeholders and market perceptions.
AuMake Limited has announced the appointment of Carl Hagon as a director, effective November 27, 2025. The initial director’s interest notice reveals that Hagon currently holds no relevant interests in securities, either as a registered holder or through other entities, nor does he have any interests in contracts related to the company. This appointment is a procedural update and does not indicate any immediate changes to the company’s operations or market strategy.
Aumake Limited announced the results of its annual general meeting, where all resolutions were passed by poll, although Resolution 2 and Resolution 3 were withdrawn. This outcome signifies a smooth operational process for the company, potentially reinforcing its strategic direction and stability in the market.
Aumake Limited has announced changes to its Board of Directors to enhance governance and operational focus. Executive Directors Joshua Zhou and Tracy Zhou have resigned from the Board to concentrate on their respective business units, while Carl Hagon, an experienced attorney, has been appointed as a Non-Executive Director. These changes aim to separate board oversight from executive management, allowing for improved governance and operational efficiency, which is expected to lead to better commercial outcomes and strategic alignment.
AuMake Limited has announced its 2025 Annual General Meeting (AGM) scheduled for November 28, 2025, at its Artarmon location. Shareholders are encouraged to participate in the meeting and vote on resolutions, either in person, by proxy, or online. The company emphasizes the use of electronic communications to keep shareholders informed efficiently, promoting environmental sustainability and cost reduction.
Aumake Limited has entered into a non-binding Cooperation Framework Agreement with Sinomach Hainan Development Co., Ltd., a subsidiary of China National Machinery Industry Corporation. This partnership marks Sinomach’s first commercial engagement in Australia and aims to develop a large-scale Premium Hay Supply Chain Project. The project will initially cover 3,000 hectares, with plans to expand to 20,000 hectares, targeting an annual production capacity of 300,000 tonnes. Aumake will manage the Australian operations, while Sinomach will provide technology, infrastructure, and capital support. This collaboration aligns with China’s broader strategy to strengthen international agricultural supply chains and offers Aumake access to Sinomach’s extensive resources and market demand.
Aumake Limited has launched Bio-Basic Ergothioneine, marking the first brand under its new capital-light incubation model. This strategy aims to develop high-margin health and wellness brands with minimal capital investment, allowing Aumake to retain acquisition rights for successful brands. The launch, supported by a partnership with Mijing Media, combines online and offline distribution channels, enhancing Aumake’s market positioning in China’s premium health market. The initiative demonstrates the viability of Aumake’s model and sets the stage for future brand developments.
AuMake Limited announced a late lodgement of Appendix 3Z related to Ms. Hai Yun Chen due to an administrative oversight. The company assured stakeholders that this is an isolated incident and affirmed their commitment to compliance with ASX Listing Rules, indicating no significant impact on their operations or industry positioning.
Aumake Limited has announced a leadership transition following the completion of a strategic review, which has provided a roadmap for focusing on high-margin growth opportunities and capital-light distribution models. The resignation of Executive Director Hai Yun Chen is part of the company’s strategy to enhance decision-making and operational focus, with aggressive cost-cutting measures underway to improve cash flow and long-term profitability. This transition marks a significant step in Aumake’s efforts to streamline operations and prioritize margin expansion, positioning the company for sustainable growth and enhanced shareholder value.
AuMake Limited has released its corporate governance statement for the financial year ending June 30, 2025, in compliance with ASX Listing Rules. The statement, available on the company’s website, outlines the extent to which AuMake has adhered to the ASX Corporate Governance Council’s recommendations. This disclosure is crucial for stakeholders as it provides transparency regarding the company’s governance practices and any deviations from recommended practices, which could impact investor confidence and the company’s market positioning.